Medpace (NASDAQ:MEDP) CEO Sells $95,572.40 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 154 shares of Medpace stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $620.60, for a total value of $95,572.40. Following the sale, the chief executive officer directly owned 389,302 shares in the company, valued at approximately $241,600,821.20. This trade represents a 0.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Medpace Trading Down 4.2%

Shares of NASDAQ MEDP opened at $598.08 on Friday. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The company has a market cap of $16.69 billion, a PE ratio of 35.06, a P/E/G ratio of 2.78 and a beta of 1.18. The stock has a 50 day simple moving average of $599.99 and a 200-day simple moving average of $520.63.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period last year, the firm earned $3.10 EPS. The firm’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: UBS upgraded Medpace from “sell” to “neutral” (effectively “hold”) and raised its price target to $673 from $405. The revised target remains above the recent trading level, suggesting UBS sees less downside risk than previously expected. UBS upgrades Medpace and raises price target
• Positive Sentiment: Medpace’s latest reported quarter showed solid momentum, with revenue increasing 17.2% year over year to $707.3 million and adjusted earnings of $4.25 per share exceeding analyst expectations. Management’s fiscal 2026 earnings guidance remains supportive of the long-term growth narrative. Medpace reports 17.2 percent revenue growth
• Neutral Sentiment: Analyst sentiment remains mixed. Several firms have “hold” ratings, while others maintain bullish views; the broader consensus is near a hold rating, indicating that expectations for Medpace’s strong growth are already reflected in its relatively high valuation.
• Negative Sentiment: CEO August Troendle sold 21,966 shares for approximately $13.7 million on September 30, following the sale of 26,701 shares worth about $16.6 million one day earlier. The combined sales totaled roughly $30.3 million and reduced his direct ownership by about 13% across the two transactions. Additional smaller reported sales add to concerns about insider confidence, even though Troendle still owns a substantial stake. Medpace CEO stock sale SEC filing

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MEDP. BlackRock Inc. acquired a new stake in Medpace in the 2nd quarter valued at about $1,323,047,000. Wasatch Advisors LP boosted its position in shares of Medpace by 19.4% during the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock valued at $371,634,000 after purchasing an additional 125,625 shares in the last quarter. State Street Corp grew its stake in shares of Medpace by 4.2% in the 2nd quarter. State Street Corp now owns 710,895 shares of the company’s stock worth $376,483,000 after purchasing an additional 28,666 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after purchasing an additional 38,760 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MEDP has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Robert W. Baird boosted their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. UBS Group began coverage on shares of Medpace in a research note on Wednesday. They issued a “neutral” rating and a $673.00 price target for the company. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Finally, BMO Capital Markets raised their price objective on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $602.27.

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.